Sanofi-Aventis Gets U.S. Approval for Use of Taxotere in Treating Head and Neck Cancer
PARIS Sanofi-Aventis announced that the Food and Drug Administration has approved the use of its cancer drug Taxotere to treat another form of the disease.
The company said Monday that the drug could now be used to treat locally advanced head and neck cancer prior to chemo radiotherapy and surgery.
The approval was based on the company’s advanced clinical trials, which concluded that patients who use Taxotere in combination with standard induction chemotherapy resulted in a more than three-year improvement in patient survival rate, the company said.
Taxotere is now approved in Europe and the United States to treat five cancer types: breast cancer, lung cancer, prostate cancer, gastric cancer, and head and neck cancer.
More than 640,000 people worldwide are diagnosed with head and neck cancer each year, and more than 350,000 die from the disease annually, the company stated in a release.
“Head and neck cancer is particularly hard to treat and if not detected early has low survival rates,” said Nancy Leupold, President and Founder of Support for People with Oral and Head and Neck Cancer. “The availability of effective therapies that advance treatment and help patients live longer is very welcome news for the cancer community.”
Senate approves equal pharmacy access for military and their families
ALEXANDRIA, Va. The National Association of Chain Drug Stores issued a letter to a New Jersey senator yesterday for his support in their fight to prevent an increase in co-payments for military beneficiaries.
Senator Frank Lautenberg, D-N.J., was thanked for sponsoring an amendment to prohibit increased co-payments to those beneficiaries using retail pharmacies in the TRICARE health benefits program. TRICARE is the military health program that provides care to over 9 million uniformed personnel, their families and retired military worldwide.
“Keeping equal access to chain community pharmacy for our U.S. military and their families is a priority for NACDS,” stated NACDS President and chief executive officer, Steve Anderson, “We applaud Senator Lautenberg’s leadership in introducing the amendment, which shows great support for our nation’s military. We look forward to continuing to work with the Senator and his colleagues to pass H.R. 1585, and continue to develop policy solutions that maximize competition and protect choice for TRICARE beneficiaries.”
The amendment was subsequently adopted as part of the National Defense Authorization Act for 2008 (H.R. 1585), which is currently being debated in the Senate. The amendment will ensure that TRICARE patients would not be inclined to use mail order rather than local retail pharmacies because of co-payment increase.
Senate passes bill for tamper-resistant prescription delay
WASHINGTON Now, it’s up to the White House.
Pharmacy leaders breathed a cautious sigh of relief today with passage in the U.S. Senate last night of a bill that would delay for six months a looming requirement that all Medicaid prescriptions to be written on tamper-resistant prescription paper. But with no time left to lose before the Oct. 1 deadline originally imposed by Congress for implementation of the new prescription pad rule, leaders at the National Association of Chain Drug Stores and the National Community Pharmacists Association immediately set their sights on convincing President Bush to sign the measure into law before Monday.
Following passage in the House of a companion measure, the Senate on Thursday night approved H.R. 3668, extending several health care programs set to expire Oct. 1. Of critical interest to pharmacy and physician groups, it also allows for a six-month delay in the tamper-proof mandate to give both professions—and state Medicaid administrators nationwide—a chance to obtain the needed pads and adapt to the new requirement.
The original mandate was written into an Iraq war funding bill with little notice, requiring all Medicaid prescriptions to be written on special tamper-resistant pads beginning Oct. 1. The rapidly approaching deadline raised alarm bells among dozens of pharmacy, physician and patient advocacy groups in recent weeks, and spawned an increasingly intense lobbying campaign to turn aside the regulation.
“Community pharmacists are aware of the problems associated across the country with Medicaid fraud,” said Bruce Roberts, executive vice president and chief executive officer of NCPA. “With a stroke of the President’s pen, the health care community will have adequate lead time to make the use of tamper-resistant pads a reality. I urge President Bush to move swiftly to approve this delay before the October 1st effective date of the law.”
NACDS president and chief executive officer Steven Anderson praised the bipartisan leadership of Ohio Senators George Voinovich, a Republican, and Democrat Sherrod Brown, for addressing the tamper-resistant requirement in a stand-alone bill earlier this week—a bill that was superseded by the extension legislation passed last night. “The determined efforts of Senator Brown, Senator Voinovich, as well as Senate Leadership, were crucial to achieving passage of this six-month delay.
“We greatly appreciate their support for community pharmacy and the Medicaid patients we serve,” Anderson said. “We also applaud the support of Finance Committee Chairman Max Baucus, D-Mont., and ranking member Charles Grassley, R-Iowa, who supported inclusion of the delay in the final health extenders legislation.”